- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Gary Lyman, MD, MPH: How Biosimilars Will Impact Price
Gary Lyman, MD, MPH, of the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, discusses how biosimilars could impact the cost of care.
Transcript
The issue is whether these biosimilars will achieve the goal of reducing prices in reducing healthcare costs. And in actual fact, data in Europe (again, they’re about 10 years ahead of us) suggest perhaps a 20% to 30% reduction in pricing when competitive by biosimilars are available in the marketplace.
We're too early to know whether we'll see that type of impact in the United States. If we do, even a 20% to 30% reduction in cost in a multibillion-dollar industry is a large amount of money, so it would be useful, but we don't know yet whether that will actually happen.
Two recent studies published in JAMA Oncology this past year, looking at the early utilization of the hematopoietic growth factor biosimilars suggest maybe about a 10% reduction in price so far, but now we have 5 competitive hematopoietic growth factor biosimilars, we now have 4 trastuzumab or Herceptin biosimilars for breast cancer patients, so as we get multiple competitors in a class of agents, there should be more competition and hopefully a greater impact on price.
Eye on Pharma: Keytruda Biosimilar Deal; German Court Bans Imraldi; New Biosimilars for Japan
June 17th 2025Alvotech and Dr. Reddy's partner to develop a Keytruda biosimilar, a German court bans Humira biosimilar over patent dispute, and Samsung Bioepis enters a strategic agreement with NIPRO Corporation in Japan.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
